# Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

> **NCT01303965** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sherif S. Farag** · enrollment: 14 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01303965
- **Lead sponsor:** Sherif S. Farag
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02-07
- **Primary completion:** 2014-09-23
- **Final completion:** 2017-07-28
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2019-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303965, "Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01303965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*